1. Scrip
  2. >>Therapy Areas

Aduhelm Label Update Includes Seizure Risk And Recommends More MRIs

 
• By Jessica Merrill

FDA updated the prescribing information for Biogen’s Alzheimer's therapy after four cases of seizures were reported.

Aduhelm's prescribing information was updated by FDA • Source: Alamy

A new safety update to the US prescribing information for Biogen, Inc.'s Aduhelm (aducanumab) – the first-of-its-kind, anti-amyloid antibody for Alzheimer's disease – presents more obstacles to use, but the drug already has been mostly sidelined by access restrictions.

The US Food and Drug Administration updated the warnings and precautions section of the label on 29 April to include...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.